GlaxoSmithKline hits speed bump en route to diabetes drug approval

GlaxoSmithKline ($GSK) hit a roadblock in its bid for approval on a new diabetes drug. The FDA asked for a few more months to review GSK's app on albiglutide, which would compete with Novo Nordisk's ($NVO) Victoza and Bristol-Myers Squibb ($BMY) and AstraZeneca's ($AZN) Byetta and Bydureon, among others. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.